Jones Day advised Nuvalent on the deal.Nuvalent, Inc. announced the establishment and prosecution of global patent portfolios related to small molecule ROS1-selective inhibitors, ALK-selective inhibitors, and HER2-selective…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
